Related Experiment Video

Updated: Jun 25, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
09:16

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes

Published on: June 3, 2018

Jumonji is a potential regulatory factor mediating nitric oxide-induced modulation of cardiac hypertrophy

Simon W Rabkin1, Shaun S Klassen

  • 1Division of Cardiology, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada. rabkin@interchange.ubc.ca

Journal of Cardiovascular Medicine (Hagerstown, Md.)
|February 6, 2009
PubMed

Insights

Jumonji (jmj) protein may counteract cardiac hypertrophy by interacting with cell cycle regulators. Increasing jmj expression could be a therapeutic strategy for heart conditions.

Area of Science:

  • Molecular Biology
  • Cardiovascular Research
  • Gene Regulation

Background:

  • Jumonji (jmj) is a key protein in the jmj domain-containing family.
  • It regulates genes involved in embryonic cardiac cell growth.
  • Its role in the mature heart remains largely unknown.

Purpose of the Study:

  • To investigate the function of jmj in the mature heart.
  • To explore the role of jmj in cardiac hypertrophy.
  • To understand the relationship between jmj, nitric oxide, and cardiac hypertrophy.

Main Methods:

  • The study proposes interactions between JMJ domain 2A family proteins and cell cycle regulators (retinoblastoma protein, cyclin D, E2F).
  • It examines the effect of nitric oxide on jmj gene and protein expression.
  • The research focuses on the molecular mechanisms underlying cardiac hypertrophy modulation.

Main Results:

  • The JMJ domain 2A family may modulate cardiac hypertrophy via interactions with cell cycle proteins, promoting cell growth.
  • Nitric oxide can inhibit cardiac hypertrophy and upregulate jmj expression.
  • jmj is identified as a potential mediator of nitric oxide's effects on cardiac hypertrophy.

Conclusions:

  • jmj may act as a critical factor counteracting cardiac hypertrophy development.
  • Biotechnology strategies to enhance jmj expression could offer a therapeutic approach.
  • This research highlights a potential new target for mitigating cardiovascular disease associated with cardiac hypertrophy.
Abstract

More Related Videos

Transverse Aortic Constriction in Mice08:25

Transverse Aortic Constriction in Mice

Published on: April 21, 2010

Related Concept Videos

Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Regulation of the Cardiovascular System01:27

Regulation of the Cardiovascular System

The regulation of the cardiovascular system allows the body to adapt to various demands and maintain homeostasis.
The regulation of the cardiovascular system involves the autonomic nervous system (ANS), baroreceptors, and chemoreceptors, ensuring that heart rate and blood pressure are appropriately modulated in response to varying physiological demands.
The ANS comprises two main divisions: the sympathetic and parasympathetic nervous systems. The sympathetic nervous system enhances...
Regulation of Heart Rates01:31

Regulation of Heart Rates

The regulation of heart rate is a complex process controlled by the autonomic nervous system (ANS), hormonal influences, and intrinsic cardiac mechanisms. The ANS has two main components: the sympathetic nervous system (SNS) and the parasympathetic nervous system (PNS).
The SNS increases heart rate through the release of norepinephrine and epinephrine, which act on beta-1 adrenergic receptors in the heart. This action increases the rate of depolarization in the sinoatrial (SA) node, the heart's...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Hormonal Regulation of Blood Pressure01:17

Hormonal Regulation of Blood Pressure

Endocrinal or hormonal intervention in the cardiovascular system is predominantly exerted by the catecholamines - epinephrine and norepinephrine, as well as a slew of hormones that interact with renal function to modulate blood volume.
Epinephrine and Norepinephrine
The adrenal medulla releases epinephrine and norepinephrine, catecholamines that enhance and extend the sympathetic or "fight or flight" physiological response. These hormones escalate heart rate and the force of contraction while...